8-K: Spectral AI Reports FY25 Results, DeepView Progress

Spectral AI, Inc. announced its fourth quarter and full year 2025 financial results, highlighting increased cash and progress towards commercializing its DeepView System for burn indication.

Summary

• Full Year 2025 Research & Development revenue was $19.7 million, a decrease from $29.6 million in FY 2024.
• Fourth Quarter 2025 Research & Development revenue was $3.8 million, down from $7.6 million in Q4 2024.
• Cash balance significantly improved to $15.4 million as of December 31, 2025, compared to $5.2 million at December 31, 2024.
• Net loss for the full year 2025 was $(7.6) million, or $(0.29) per diluted share, a substantial improvement from a net loss of $(15.3) million, or $(0.85) per diluted share in FY 2024.
• Net income for Q4 2025 was $0.6 million, or $0.02 per diluted share, compared to a net loss of $(7.7) million, or $(0.41) per diluted share in Q4 2024.
• The company submitted its De Novo 510(k) application to the U.S. Food and Drug Administration (FDA) for its DeepView System for burn indication.
• Received an additional $31.7 million in non-dilutive funding from the Biomedical Advanced Research and Development Authority (BARDA), bringing total committed BARDA funding to $54.9 million as part of a contract valued up to $150.0 million.
• The company committed to provide an additional $9.7 million to the total overall development costs associated with these BARDA-funded feature advancements.
• Spectral AI forecasts revenue of approximately $18.5 million for the year ending December 31, 2026, primarily from the BARDA PBS Contract, excluding material contributions from DeepView System sales for burn indication.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by significant cash growth, reduced net losses, and critical progress in FDA submission and BARDA funding, despite a decline in R&D revenue and a conservative 2026 revenue outlook.

Positives

• Cash balance significantly increased to $15.4 million at year-end 2025 from $5.2 million in 2024, reflecting debt and equity financings, as well as warrant and stock option exercises.
• Net income for Q4 2025 was $0.6 million, a significant improvement from a net loss of $(7.7) million in Q4 2024.
• Full year 2025 net loss reduced to $(7.6) million from $(15.3) million in FY 2024, primarily due to the change in fair value of warrant liability, reduced borrowing-related costs, and improved operating efficiencies.
• Submission of De Novo 510(k) application to the FDA for DeepView System burn indication marks a pivotal step towards commercialization.
• Received $31.7 million in immediate, non-dilutive funding from BARDA to accelerate and support the development of additional DeepView System features.
• Total committed BARDA funding now stands at $54.9 million, part of a larger contract valued at up to $150.0 million.
• General and administrative expenses decreased in Q4 2025 and FY 2025, reflecting a continued focus on operating efficiencies.

Negatives

• Research & Development revenue decreased in Q4 2025 to $3.8 million from $7.6 million in Q4 2024, reflecting an anticipated reduction in reimbursed costs as the company moved closer to completion of the base phase of its BARDA contract.
• Full year 2025 R&D revenue decreased to $19.7 million from $29.6 million in FY 2024, reflecting the anticipated overall reduction in reimbursed costs associated with the BARDA PBS Contract.
• Q4 2025 gross margin decreased to 39.8% from 44.0% in Q4 2024, primarily due to a lower percentage of reimbursed direct labor as a component of overall revenue from the BARDA PBS Contract.
• Operating loss increased in Q4 2025 to $(2.481) million from $(1.111) million in Q4 2024.
• Operating loss increased for FY 2025 to $(8.603) million from $(6.582) million in FY 2024.
• The 2026 revenue guidance of $18.5 million is lower than the FY 2025 revenue of $19.7 million.
• The 2026 guidance explicitly does not include any material contributions from the sale of the DeepView System for the burn indication, indicating commercialization revenue is not expected in the near term.

Risks

• The filing refers to risks and uncertainties described in the Risk Factors sections of the Company's other filings with the SEC, including the Registration Statement, but does not detail specific risks within this report.

Future Outlook

Spectral AI forecasts revenue of approximately $18.5 million for the year ending December 31, 2026, primarily reflecting the continued development of its DeepView System through the BARDA PBS Contract. This guidance explicitly does not include any material contributions from the sale of the DeepView System for the burn indication.

Management Comments

• "2025 was a pivotal year for Spectral AI, highlighted by the submission of our De Novo 510(k) application to the U.S. Food and Drug Administration (FDA) of our DeepView System for burn indication." Vincent Capone, Chief Executive Officer.
• "We continue to make significant progress along numerous fronts in preparation for the anticipated commercialization of this innovative diagnostic device. The reception of our technology at burn conferences in the U.S., UK, and Europe has been exceptional." Vincent Capone, Chief Executive Officer.
• "We ended the year in a strong financial position, especially with our cash balance above $15.0 million at year-end, and we continue to manage expenses to ensure that spending aligns with our strategic priorities and commercialization." Vincent Capone, Chief Executive Officer.
• "We are confident that we have the people, processes, and platform in place to prepare for the next exciting phase of our growth." Vincent Capone, Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Spectral AI's focus on AI-driven medical diagnostics for wound care, particularly burns, positions it in a high-growth segment of health tech. The substantial non-dilutive funding from BARDA underscores the strategic importance and potential of its DeepView System, aligning with broader industry trends towards leveraging AI for faster, more accurate diagnostic decisions and reducing healthcare costs. The FDA submission is a critical step towards market entry in a field where innovation can significantly improve patient outcomes.

Comparison to Industry Standards

• The DeepView System is being developed with a goal of exceeding the current standard of care in the future for burn wound assessment.
• Spectral AI has been named to TIME's list of Worlds Top HealthTech companies 2025, indicating recognition within the broader health tech industry.
• The filing does not provide specific comparisons to other companies, projects, or their results within the industry.

Stakeholder Impact

• Shareholders: Potential positive impact from reduced net losses, increased cash, and significant progress towards FDA approval and commercialization of the DeepView System, indicating long-term growth potential.
• Employees: Continued development and commercialization efforts suggest stable to growing employment opportunities, particularly in R&D and commercialization roles.
• Customers (Healthcare Providers/Patients): Anticipated benefit from the DeepView System offering faster and more accurate treatment decisions in wound care, potentially improving patient outcomes and reducing healthcare costs.
• Creditors: Improved cash position and reduced net losses enhance the company's financial stability, potentially reducing credit risk.
• BARDA: Continued collaboration and funding commitment for DeepView System development reinforces the strategic partnership.

Next Steps

• Continued progress towards the anticipated commercialization of the DeepView System for burn indication.
• Ongoing development of additional feature aspects for the DeepView System, supported by BARDA funding.
• The company hosted a conference call on March 24, 2026, to discuss these results, with a replay available on its website.

Key Dates

Recommendation

While Spectral AI demonstrated significant improvements in cash position and reduced net losses, alongside critical progress in FDA submission and substantial non-dilutive BARDA funding, the decline in R&D revenue and a conservative 2026 revenue guidance that excludes DeepView sales suggest that commercialization revenue is still some time away. The stock may experience volatility as investors weigh the long-term potential against the near-term revenue outlook and continued reliance on grant funding. A "Hold" recommendation allows investors to monitor the progress of FDA approval and initial commercialization efforts without taking on immediate additional risk or exiting a potentially promising long-term position.

Keywords

Spectral AI, MDAI, DeepView System, AI medical diagnostics, wound care, burn indication, FDA 510(k), BARDA funding, financial results, Q4 2025, FY 2025, artificial intelligence, health tech